#tagrisso

Tuesday February 2nd    2.2.2021     Rising trend of young celebrities passing from cancer.  Colon cancer  and now lung cancer caught at late stages seems such a shame.  

At 44, Dustin Diamond, for whom the Bell tolled on Monday 2.1.21, played the roll of Samuel Screech Powers on the teenage staple “Saved by the Bell.”  He took his first round of chemotherapy recently and passed soon after.  It turns out that the chemo fatally toxic side effects to his “treatment” may very well be what killed him. 

Take a look at the serious side effects of one drug used for lung cancer treatment called Tagrisso.  Fatal effects of the lungs and heart.

The lungs having to do with keywords and themes of 2020 virus like, ventilators, respiration, breathing, inspiration, exhalation, and pneumonia.  The running theme of Corona, Covid-19, Protests, Police brutality, and Capitol insurrection.  CAPS was Event 201 syndrome predicted by simulation on 18th of October, 2019.

What does Osimertinib (AZD9291) mean?

Osimertinib is a drug salt used to develop anti-cancer medication for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and certain other tumor cases. It is also available in the market by its international brand name Tagrisso which is an AstraZeneca Pharmaceuticals product. It is also known by its chemical name AZD9291 and was previously known as Mereletinib.

 What are the uses of Osimertinib?

It is an anti-cancer medication used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC), and many other cancer cases.

 What are the forms & strengths of Tagrix?

It is available in 40mg & 80mg power tablet form for oral use.

 Osimertinib Tablet Brands and their respective manufacturers

All brands come in the form of 40 mg and 80 mg power tablets. Few available brands are and their manufactures are as follows:

Tagrix by Beacon Pharmaceuticals.

Osicent by Incepta Pharmaceuticals.

Tagrisso by AstraZeneca Pharmaceuticals.

Osim by Caprane Pharmaceutical Pvt. Ltd.

Osimert by Everest Pharma.

TagAsso by Asso Pharmaceuticals.

Luciosim by Lucius Pharma.

Irmukin by Genvio Pharma Limited.

Above all and many more.

How to take Osimertinib tablets?

It is available in the form of tablets, so, as recommended by the doctor, it is taken orally by ingesting it with the aid of water and dosage as much as prescribed.

 How does Tagrisso 80mg work?

By growing their proliferation in other parts of the body, immune cells have the ability to transform healthy cells into dead cells. Thus, Osimertinib joins the cancer cells and reduces their improved potential. It doesn't make them do any harm or spread further.

 Osimertinib side-effects

Following are a couple of adverse post effects reported in patients receiving Osimertinib (AZD9291) tablets:

Diarrhea

Rashes

Mouth sores

Tiredness

Stomatitis

Dry & Itchy Skin

Toenails skin

Low neutrophil counts.

Low platelet count

Low white blood cell counts (leukocyte).

Interstitial lung disease and so on.

           All post-effects are not listed above, so after taking Osimertinib tablets, if you feel any of the above or any other related changes in your/patient body, then visit the doctor promptly and let him/her know about it.

 Best place to Buy Osimertinib tablets brands online at wholesale price.

MedsDots.net, a true Indian pharmacy is the wholesale supplier of both non-generic & generic Tagrisso tablet and its alternate relative brands as well as other rare and targeted life-saving medicines too.

 Why MedsDots.net?

We are a leading and trustworthy provider of medication around the world, and since every customer needs the best, we have confidence in faith and loyalty to the consistency of the substance. Our few main features are as follows:-

100% quality assured.

Indian as well as overseas medical supplier.

Trustworthy in quality of products as well in prices of the products too.

Quickest delivery pledge around 150+ countries at your doorstep.

More than 10000000+ satisfied customers.

Serve rare and targeted life-saving quality medicines

 Countries where we shipped.

MedsDots serves its services successfully around worldwide countries including the USA, China, HongKong, Australia, UK, Jordan, Saudi, Malaysia, UAE, Singapore, Ukraine, Russia, Vietnam, Philippines, Poland, Romania, Hungary, Taiwan, New Zealand, and almost anywhere in the world.

 How to connect MedsDots?

DESCRIPTION

              Tagrisso 80mg

A Tagrisso 80mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.

Tagrisso 80mg is considered as third generation medicine, which is available in tablet form.

Tagrisso 80mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.

The pharmacological category of Tagrisso 80mg tablet is tyrosine kinase prohibitor.

INDICATION

                                                   Tagrisso 80mg

A Tagrisso 80mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.

Tagrisso 80mg tablet is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.

MECHANISM OF ACTION

                                                 Tagrisso 80mg

PROPERTIES                    

      Ingredients : Bevacizumab                  

     Strength     : 100mg/4ml                       

     Package     : 400mg of Bevacizumab containing vial

ADME PROPERTIES

Absorption :

High plasma concentration time of Osimeritinib reaches within 6 hours

Distribution :

Volume of distribution 918L

Human Plasma protein bound to Osimeritinib is 95%

Metabolism :

The metabolism of Osimeritinib is occurs via oxidation.

The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104

Excretion :

The mean terminal half-life period 48 hours

Clearance value 14.3L/hr

68% of metabolite is excreted in feces; 14% through urine

2% of unchanged form of drug is eliminated

DOSAGE MANAGEMENT

The recommended dosage of Tagrisso 80mg tablets are, 80mg tablet should be taken as a single dose.

Tagrisso tablet should be administered with or without food.

If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.

Tagrisso tablet do not break, crush or chew.

Interrupt the treatment during the conditions like;

Interstitial lung disease

QT prolongation

Symptomatic congestive heart failure

In pain management

Grade III or severe: discontinue the Tagrisso tablet for 3 weeks

Grade 0 to II: follow at 80mg or 40mg as a single dose

If no development in 3 weeks: Discontinue the therapy.

While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso 80mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.

PRECAUTIONS

Interstitial lung disease:

Tagrisso  80mg

To avoid this problem, withheld or stop the Tagrisso 80mg tablets.

Keratitis:

Tagrisso 80mg

check the manifestation of keratitis regularly and provide supportive measures

Embryo fetal toxicity:

Tagrisso 80mg

Tagrisso 80mg tablet required in pregnancy period causes fetal damage.

QTc extension:

Do not concurrent use of Tagrisso 80mg with drug prolong the QTc

Cardiomyopathy:

Tagrisso 80mg

Periodic cardiac monitoring is assessed; in this condition stop the therapy.

SIDE EFFECTS

The most common adverse effects occurred during the therapy;

Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis.

Other common side effect :

Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia, Thrombocytopenia, Anemia, Neutropenia.

PREGNANCY

Pregnancy category of Osimeritinib is not designate

While using Tagrisso 80mg tablet causes possible for fetal harm.

LACTATION

Milk feeding should not be taken during lactation period.

STORAGE

The Tagrisso 80mg tablet is, stored at 25°C.

Keep the tablet carton from moisture, heat and light.

MISSED DOSE

In case of missed dose, do not take the missed dose and follow the regular dosing schedule.

CONTACT US

PHONE NO:+91-9940472902 EMAIL       :[email protected]  WEBSITE  :

DESCRIPTION

                                                         Tagrisso 40mg

A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.

Tagrisso 40mg is considered as third generation medicine, which is available in tablet form.

Tagrisso 40mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.

The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor.

INDICATION

              Tagrisso 40mg

A Tagrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.

Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.

MECHANISM OF ACTION

                                                        Tagrisso 40mg

Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor drugs.

Osimeritinib is named tyrosine kinase inhibitor of epidermal development factor receptor which is available on the surface of tumor cells

Osimeritinib is non-reversibly converge with mutant type of EGFR at 9 folds than wild sort

Forbids EGFR sharpening changes exon 19 Del and L858R

Prompts denies transformed EGFR with T790M opposition transformation

At last, bring down action against wild kind EGFR

Tagrisso 40mg

PROPERTIES                                              

Ingredients : Osimeritinib

Strength : 40mg

Package : 30 tablets in a carton

ADME

Absorption :

High plasma concentration time of Osimeritinib reaches within 6 hours

Distribution :

Volume of distribution 918L

Human Plasma protein bound to Osimeritinib is 95%

Metabolism :

The metabolism of Osimeritinib is occurs via oxidation.

The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104

Excretion :

The mean terminal half-life period 48 hours

Clearance value 14.3L/hr

68% of metabolite is excreted in feces; 14% through urine

2% of unchanged form of drug is eliminated

DOSAGE MANAGEMENT

The recommended dosage of Tagrisso tablet are, 80mg tablet should be taken as a single dose.

Tagrisso 40mg tablet should be administered with or without food.

If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.

Tagrisso tablet do not break, crush or chew.

Interrupt the treatment during the conditions like;

Interstitial lung disease

QT prolongation

Symptomatic congestive heart failure

In pain management

Grade III or severe: discontinue the Tagrisso 40mg tablet for 3 weeks

Grade 0 to II: follow at 80mg or 40mg as a single dose

If no development in 3 weeks: Discontinue the therapy.

While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.

PRECAUTIONS

nterstitial lung disease:

To avoid this problem, withheld or stop the Tagrisso 40mg tablets.

Keratitis:

check the manifestation of keratitis regularly and provide supportive measures

Embryo fetal toxicity:

Tagrisso 40mg tablet required in pregnancy period causes fetal damage.

QTc extension:

Do not concurrent use of Tagrisso 40mg with drug prolong the QTc

Cardiomyopathy:

Periodic cardiac monitoring is assessed; in this condition stop the therapy.

SIDE EFFECTS

Tagrisso 40mg

   The most common adverse effects occurred during the therapy;

   Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis.

Other common side effect :

                                                     Tagrisso 40mg

Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST &  ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia,Thrombocytopenia, Anemia, Neutropenia.

PREGNANCY

Pregnancy category of Osimeritinib is not designate

While using Tagrisso 40mg tablet causes possible for fetal harm

LACTATION

Milk feeding should not be taken during lactation period.

STORAGE

The Tagrisso 40mg tablet is, stored at 25°C.

Keep the tablet carton from moisture, heat and light.

MISSED DOSE

In case of missed dose, do not take the missed dose and follow the regular dosing schedule.

CONTACT US

PHONE NO:     +91-9940472902

EMAIL:           [email protected]